T0	Outcomes 10 40	5α-reductase type 2 expression
T1	Outcomes 122 161	with decreased tumor cell proliferation
T2	Outcomes 164 221	Tumor cell proliferation and progression of breast cancer
T3	Outcomes 692 703	the effects
T4	Outcomes 715 893	the expression of enzymes involved in intratumoral androgen production including 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), 5α-reductase types 1 and 2 (5αRed1 and 5αRed2)
T5	Outcomes 897 934	well as androgen receptor (AR) levels
T6	Outcomes 954 1026	findings with therapeutic responses including Ki67 labeling index (Ki67)
T7	Outcomes 1232 1265	status of 17βHSD5, 5αRed1, 5αRed2
T8	Outcomes 1345 1373	increments of 5αRed2 as well
T9	Outcomes 1417 1428	group whose
T10	Outcomes 1533 1552	increment of 5αRed2
T11	Outcomes 1589 1599	associated
T12	Outcomes 1666 1687	that increased 5αRed2